Bio/Pharma CapEx Trends 2016
Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.
Having spent over $150 billion for new plant and equipment in the past 5 years, it’s clear that global bio/pharma companies would rather…
Dose CMOs by the Numbers: Composition, Size, Market Share and Outlook
This proprietary report is based on PharmSource’s expert quantitative analysis of the contract dose manufacturing market. It will help you understand the events behind both organic and inorganic revenue changes.
PharmSource’s experts explain the relative market shares of solid, semi-solid/liquid/injectable and…
Contract Manufacturing Market Opportunities for Antibody Drug Conjugates
This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.
The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company…